{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-103974","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.672081+00:00","generated_at":"2026-05-17T01:27:01.080628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98","bullets":["Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.","KEYTRUDA sales $8.1B (+10%); WINREVAIR $360M (+141%); GARDASIL down 24% to $1.7B.","Full-year 2025 sales guidance raised to $64.5-65.0B; non-GAAP EPS raised to $8.93-8.98.","Completed acquisition of Verona Pharma (OHTUVAYRE) in October 2025.","FDA approved KEYTRUDA QLEX subcutaneous injection for all solid tumor indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-103974","json":"https://secwatch.observer/filing/0001104659-25-103974.json","markdown":"https://secwatch.observer/filing/0001104659-25-103974.md","text":"https://secwatch.observer/filing/0001104659-25-103974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/0001104659-25-103974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:27:01.080628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}